Trazimera is paid 83.6% below Herceptin

6 biosimilars bill against Herceptin (J9355). On average they are paid ↓ 46.0% relative to the reference product per 10 MG in 4Q26.

Herceptin (reference)
Trazimera
Ogivri
Hercessi
Ontruzant
Herzuma
Kanjinti

Payment limit per 10 MG, last 8 quarters. Reference product as the thick navy line, biosimilars in teal and other colors.

All products

Product	Code	CMS description	Per 10 MG	vs. reference	CMS 8% add-on note
Herceptin	J9355	Inj trastuzumab excl biosimi	$68.871	Reference	–
Trazimera	Q5116	Inj., trazimera, 10 mg	$11.271	↓ 83.6%	Yes
Ogivri	Q5114	Inj ogivri 10 mg	$29.507	↓ 57.2%	Yes
Hercessi	Q5146	Inj, hercessi, 10 mg	$30.255	↓ 56.1%	Yes
Ontruzant	Q5112	Inj ontruzant 10 mg	$32.791	↓ 52.4%	Yes
Herzuma	Q5113	Inj herzuma 10 mg	$55.295	↓ 19.7%	Yes
Kanjinti	Q5117	Inj., kanjinti, 10 mg	$63.871	↓ 7.3%	Yes

Payment limits are from the CMS 4Q26 file. Which products are grouped together comes from the site’s biosimilar groups list (reference/biosimilar_groups/2026-10-17T183707Z_d3109bb50c53.csv), checked by hand; it is not a CMS file. “CMS 8% add-on note” shows whether CMS’s notes say the 8% of reference product add-on was applied.

Medicare Part B usage

Trastuzumab market in Medicare

$258.1M Medicare Part B spending, 2025 (preliminary)

123,997 claims in 2025 (preliminary); 5,958,805.8 billing units (10 mg each) in 2024

84.4% of 2025 claims were for biosimilars, vs. 81.4% in 2024

$51.2M spending so far in 2026 (Q1, preliminary)

Spending by product

Market share (share of claims)

Herceptin (reference)
Trazimera
Ogivri
Hercessi
Ontruzant
Herzuma
Kanjinti
All biosimilars (share chart)

Medicare Part B fee-for-service spending and claims by calendar year. Years marked “prelim.” come from CMS’s quarterly spending file and will be replaced when CMS publishes the yearly file. Market share is each product’s percent of the group’s claims that year; claims are used because the quarterly file has no dosage units. A product with no bar for a year is not in CMS’s file for that year.

By product

Product	Spending 2024	Units 2024	Spending per unit 2024	Spending 2025 (prelim.)	Claims 2025	Share of claims 2025	Spending 2026 (Q1)
Herceptin J9355	$92,619,459.81	1,195,617	$77.46582711	$69,607,008.02	19,299	15.6%	$13,837,272.65
Trazimera Q5116	$18,608,785.53	1,248,857	$14.90065358	$24,598,553.28	22,877	18.4%	$1,517,118.18
Ogivri Q5114	$90,770,180.71	1,686,570	$53.81939719	$78,123,051.24	38,655	31.2%	$11,514,624.87
Hercessi Q5146	–	–	–	$28,674,172.73	10,170	8.2%	$5,849,369.03
Ontruzant Q5112	$18,977,485.54	546,170.8	$34.74643013	$6,995,844.71	6,696	5.4%	$1,650,490.42
Herzuma Q5113	$7,819,988.84	146,258	$53.46708447	$11,502,095.52	3,599	2.9%	$4,426,657.77
Kanjinti Q5117	$20,532,125.76	1,135,333	$18.08467274	$38,649,065.34	22,701	18.3%	$12,448,963.50

Spending, units and claims are CMS figures; spending per unit is CMS’s own average for 2024. Units are billing units, which can differ between codes, so compare units only between codes billed per the same amount. Shares are this site’s calculation from CMS claims. CMS may count spending differently in its quarterly and yearly files, so treat changes between 2024 and 2025 with care.

Physician-billed use by state, 2024

From CMS’s Physician & Other Practitioners by Geography and Service file, which covers drugs billed by physicians and other practitioners, mostly in offices. Drugs billed by hospital outpatient departments are not in it. For these products it covers 36.1% of 2024 Medicare units. CMS leaves out a state’s row for a product when fewer than 11 patients received it, so small states may undercount.

Hover over a state to see its figure. Territories and states with no data are in the table.

Show 40 states and territories

State	Services (billing units)	Biosimilar share
California	256,832	82.6%
Florida	226,714	88.6%
Texas	200,597	92.6%
Virginia	96,507	86.2%
Illinois	89,612	85.4%
Arizona	79,292	92.0%
Tennessee	77,343	73.5%
New York	77,125.8	74.2%
Maryland	67,976	86.8%
New Jersey	63,037	75.0%
Georgia	58,506	88.5%
Ohio	56,920	80.7%
Alabama	55,025	100.0%
Pennsylvania	47,879	90.0%
Arkansas	43,132	100.0%
Kansas	40,998	22.1%
South Carolina	37,420	100.0%
Iowa	37,019	88.3%
Minnesota	36,690	81.4%
North Carolina	34,249	91.3%
Nebraska	31,739	100.0%
Missouri	29,562	72.5%
Colorado	28,104	100.0%
Washington	27,614	100.0%
Nevada	24,424	92.0%
Michigan	22,797	100.0%
Mississippi	21,848	75.5%
Oregon	17,778	100.0%
Indiana	16,202	100.0%
Oklahoma	14,103	100.0%
Wisconsin	11,460	100.0%
Utah	10,674	100.0%
Alaska	8,948	0.0%
New Mexico	7,394	55.8%
Massachusetts	7,239	57.7%
Maine	5,515	100.0%
Wyoming	5,253	100.0%
Louisiana	5,035	100.0%
Delaware	3,477	100.0%
Rhode Island	2,332	100.0%

Sources: 2026-06-25_DSD_PTB_RY26_P06_V10_DYT24_HCPCS-260602.csv, 2026-05-21_MUP_PHY_R26_P05_V10_D24_Geo.csv.gz, 2026-07-23_qddptb_r2603_p06_v10_dqt2601_260722.csv (data.cms.gov).